Raymond Hohl, MD, PhD
Director, Penn State Cancer Institute
University Professorship in Oncology, Department of Medicine
Professor, Department of Pharmacology
Cancer Institute, Experimental Therapeutics
Type (descending)
Type(ascending)
Anti-cancer therapy: Targeting the mevalonate pathway
Swanson, K. M. & Hohl, R. J., Feb 1 2006, In : Current Cancer Drug Targets. 6, 1, p. 15-37 23 p.
Mevalonic Acid
Transferases
Cancer and the dopamine D2 receptor: A pharmacological perspective
Weissenrieder, J. S., Neighbors, J. D., Mailman, R. B. & Hohl, R. J., Jan 1 2019, In : Journal of Pharmacology and Experimental Therapeutics. 370, 1, p. 111-126 16 p.
Clinical pharmacology as a foundation for translational science
Waldman, S. A., Hohl, R. J., Kearns, G. L., Swan, S. J. & Terzic, A., Jul 1 2011, In : Clinical pharmacology and therapeutics. 90, 1, p. 10-13 4 p.
National Institutes of Health (U.S.)
Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft
Lee, C. K., de Magalhaes-Silverman, M., Hohl, R. J., Hayashi, M., Buatti, J., Wen, B. C., Schlueter, A., Strauss, R. G. & Gingrich, R. D., Jan 1 2003, In : Bone Marrow Transplantation. 31, 2, p. 121-128 8 p.
Graft vs Host Disease
Isoprenoids: Remarkable diversity of form and function
Holstein, S. A. & Hohl, R. J., Apr 1 2004, In : Lipids. 39, 4, p. 293-309 17 p.
Hydroxymethylglutaryl CoA Reductases
Critical Pathways
Is there a future for prenyltransferase inhibitors in cancer therapy?
Holstein, S. A. & Hohl, R., Jan 1 2012, In : Current Opinion in Pharmacology. 12, 6, p. 704-709 6 p.
Dimethylallyltranstransferase
Farnesyltranstransferase
Prenylation
Nonmalignant complications of therapy for Hodgkin's disease
Hohl, R. & Schilsky, R. L., Jan 1 1989, In : Hematology/Oncology Clinics of North America. 3, 2, p. 331-343 13 p.
Hodgkin Disease
Virus Diseases
Schweinfurthins: Lipid Modulators with Promising Anticancer Activity
Koubek, E. J., Weissenrieder, J. S., Neighbors, J. & Hohl, R., Aug 1 2018, In : Lipids. 53, 8, p. 767-784 18 p.
trans-Golgi Network
The intermediate enzymes of isoprenoid metabolism as anticancer targets
Wiemer, A. J., Hohl, R. & Wiemer, D. F., Jan 1 2009, In : Anti-Cancer Agents in Medicinal Chemistry. 9, 5, p. 526-542 17 p.
mevalonate kinase
Therapeutic additions and possible deletions in oncology in 2011
Holstein, S. A. & Hohl, R., Jan 1 2012, In : Clinical pharmacology and therapeutics. 91, 1, p. 15-17 3 p.
United States Food and Drug Administration
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Non-Hodgkin's Lymphoma
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
Jia, B., Wang, L., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Rizvi, S., Shike, H., Bayerl, M., Schell, T. D., Hohl, R. J. & Zheng, H., Mar 1 2018, In : Blood Cancer Journal. 8, 3, 34.
Iowa newborn hemoglobinopathy screening and comprehensive care: A model for rural states [1]
Peters, C., Miller, J., Abel, S. L., McMillan, S. K., Getchell, J. P., Giller, R. H., Hohl, R. & De Alarcon, P. A., Nov 6 1996, In : Journal of Pediatric Hematology/Oncology. 18, 4, p. 416-418 3 p.
Hemoglobinopathies
Mass Screening
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S. L., Bhushan, V., Shammo, J., Hohl, R., Verma, A., Garcia-Manero, G., Li, Y. P., Lowe, A., Zhu, J. & List, A. F., Apr 1 2013, In : Leukemia. 27, 4, p. 977-980 4 p.
Drug Dose Response Relationship
Mitogen-Activated Protein Kinase 14
Myelodysplastic Syndromes
Protein Kinase Inhibitors
Anticoagulants: Major Advances Without Clear Consensus
Hohl, R. J., Aug 1 2016, In : Clinical pharmacology and therapeutics. p. 116-118 3 p.
Cancer Therapy: Shooting for the Moon
Lee, J. S. H., Blumenthal, G. M., Hohl, R. & Huang, S. M., May 1 2017, In : Clinical pharmacology and therapeutics. 101, 5, p. 552-558 7 p.
Clinical pharmacology: Bridging discovery and practice
Hohl, R., Jun 1 2007, In : Clinical Pharmacology and Therapeutics. 81, 6, p. 783-785 3 p.
Drug development (and academic medicine): charting the course forward
Hohl, R., Nov 1 2014, In : Clinical Pharmacology and Therapeutics. 96, 5, p. 519-522 4 p.
Imaging as a biomarker for therapy response: Cancer as a prototype for the creation of research resources
McLennan, G., Clarke, L. & Hohl, R., Oct 1 2008, In : Clinical pharmacology and therapeutics. 84, 4, p. 433-436 4 p.
Factual Databases
Interdisciplinary Communication
Radiology Information Systems
National Cancer Institute (U.S.)
Oncology trial design: More accurately and efficiently advancing the field
Hohl, R., May 1 2015, In : Clinical Pharmacology and Therapeutics. 97, 5, p. 430-432 3 p.
Molecular Targeted Therapy
Off-Label Use
Vascular medicine: A look forward
Holstein, S. A. & Hohl, R. J., Aug 1 2009, In : Clinical pharmacology and therapeutics. 86, 2, p. 117-119 3 p.
Coronary Restenosis
Anticholesteremic Agents
Cardiovascular Agents
Drug-Eluting Stents
Drug Design
Comment/debate
Erratum: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies (Cancer Chemotherapy and Pharmacology 57, (155-164) DOI: 10.1007/s00280-005-0013-8)
Holstein, S. A., Knapp, H. R., Clamon, G. H., Murry, D. J. & Hohl, R., Mar 1 2007, In : Cancer Chemotherapy and Pharmacology. 59, 4, 1 p.
Erratum: O2 ⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate (Cancer Cell (2017) 32 (2)(268) (S1535610817300624) (10.1016/j.ccell.2017.02.018))
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., Berg, D. J., Zhang, J., Keech, J., Parekh, K. R., Bhatia, S., Monga, V., Bodeker, K. L., Ahmann, L., Vollstedt, S., Brown, H. & 15 others, Kauffman, E. P. S., Schall, M. E., Hohl, R., Clamon, G. H., Greenlee, J. D., Howard, M. A., Schultz, M. K., Smith, B. J., Riley, D. P., Domann, F. E., Cullen, J. J., Buettner, G. R., Buatti, J. M., Spitz, D. R. & Allen, B. G., Aug 14 2017, In : Cancer Cell. 32, 2, 1 p.
Erratum: Interaction of cytosine arabinoside and lovastatin in human leukemia cells (Leukemia Research (2001) 25 (651-660) PII: S0145212600001624)
Holstein, S. A. & Hohl, R., Apr 6 2002, In : Leukemia Research. 26, 5, 1 p.
Cytarabine
Modulation of RAS expression in human malignant cells by dietary supplements
Lewis, K. A. & Hohl, R., Jan 1 1997, In : Nutrition. 13, 10, p. 921-923 3 p.
Inhibition of Farnesyl and Geranylgeranyl Diphosphate Synthases
Holstein, S. A. & Hohl, R., Jan 1 2011, Enzymes. Academic Press, p. 301-319 19 p. (Enzymes; vol. 30).
Geranyltranstransferase
Protein Prenylation
Diphosphates
Isoprenoid regulation of the expression of ras and ras-related proteins
Holstein, S. A. & Hohl, R., Jan 1 2005, Nutrients and Cell Signaling. CRC Press, p. 439-460 22 p.
2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization
Cermak, D. M., Wiemer, D. F., Lewis, K. & Hohl, R., Nov 27 2000, In : Bioorganic and Medicinal Chemistry. 8, 12, p. 2729-2737 9 p.
Organophosphonates
Phosphorous Acids
3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines
Kuder, C. H., Weivoda, M. M., Zhang, Y., Zhu, J., Neighbors, J. D., Wiemer, D. F. & Hohl, R. J., Dec 1 2015, In : Lipids. 50, 12, p. 1195-1207 13 p.
Cultured Cells
A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep
Veng-Pedersen, P., Chapel, S., Al-Huniti, N. H., Schmidt, R. L., Sedars, E. M., Hohl, R. J. & Widness, J. A., Aug 1 2003, In : Journal of Pharmacology and Experimental Therapeutics. 306, 2, p. 532-537 6 p.
Erythropoietin Receptors
Erythroid Precursor Cells
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation
Lee, C. K., de Magalhaes-Silverman, M., Hayashi, M., Schlueter, A., Strauss, R. G., Hohl, R. J. & Gingrich, R. D., Jan 1 2002, In : Bone Marrow Transplantation. 29, 8, p. 647-652 6 p.
Mitoxantrone
Ifosfamide
Allogeneic hematopoietic stem cell (hsct) in patients with advanced hematological diseases using a non-myeloablative conditioning regimen
Lee, C. K., Hohl, R., Masaki, H., Schlueter, A., Field, E. & Gingrich, R. D., Dec 1 2000, In : Blood. 96, 11 PART II
Hematologic Diseases
A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro
Wasko, B. M., Smits, J. P., Shull, L. W., Wiemer, D. F. & Hohl, R. J., Nov 1 2011, In : Journal of Lipid Research. 52, 11, p. 1957-1964 8 p.
zoledronic acid
Farnesyl-Diphosphate Farnesyltransferase
A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: A phase II study
Gingrich, R. D., Lee, C. K., Hohl, R., Joyce, J., Burns, L. J., Tamaki, K., Wen, B. C. & Scott, S., Jan 1 1999, In : Biology of Blood and Marrow Transplantation. 5, 2, p. 86-93 8 p.
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
Messing, E., Gee, J. R., Saltzstein, D. R., Kim, K. M., DiSant'Agnese, A., Kolesar, J., Harris, L., Faerber, A., Havighurst, T., Young, J. M., Efros, M., Getzenberg, R. H., Wheeler, M. A., Tangrea, J., Parnes, H., House, M., Busby, J. E., Hohl, R. & Bailey, H., Apr 1 2012, In : Cancer Prevention Research. 5, 4, p. 621-630 10 p.
Chemoprevention
Tumor Biomarkers
A phase-I, dose escalation study for salvage chemotherapy for patients with refractory lymphoma, prior to myeloablative therapy with stem cell transplantation
Choon-Kee, L., De Magalhaes-Silverman, M., Hohl, R., Hayashi, M., Schlueter, A. & Gingrich, R. D., 2000, In : Blood. 96, 11 PART II
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
Venook, A. P., Klein, C. E., Fleming, G., Hollis, D., Leichman, C. G., Hohl, R., Byrd, J., Budman, D., Villalona, M., Marshall, J., Rosner, G. L., Ramirez, J., Kastrissios, H. & Ratain, M. J., Dec 1 2003, In : Annals of Oncology. 14, 12, p. 1783-1790 8 p.
A phase II study of temozolemide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. G., Vick, N. A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D. & 2 others, Zaknoen, S. & Levin, V. A., Aug 31 2000, In : British Journal of Cancer. 83, 5, p. 588-593 6 p.
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
Bailey, H. H., Wilding, G., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Simon, K., Marnocha, R., Holstein, S. A., Stewart, J., Lewis, K. A. & Hohl, R., Oct 1 2004, In : Cancer Chemotherapy and Pharmacology. 54, 4, p. 368-376 9 p.
perilla alcohol
Plasmas
Biologically active biotin derivatives of schweinfurthin F
Ulrich, N. C., Kuder, C. H., Hohl, R. & Wiemer, D. F., Nov 15 2010, In : Bioorganic and Medicinal Chemistry Letters. 20, 22, p. 6716-6720 5 p.
Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate
Wasko, B. M., Dudakovic, A. & Hohl, R. J., May 1 2011, In : Journal of Pharmacology and Experimental Therapeutics. 337, 2, p. 540-546 7 p.
Diphosphonates
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
Zhu, L., Kong, Y., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Palmisiano, N. D., Wang, M., Jia, B., Bayerl, M., Schell, T. D., Hohl, R. J., Zeng, H. & Zheng, H., Jun 19 2017, In : Journal of Hematology and Oncology. 10, 1, 124.
Brain cholesterol metabolism and Parkinson's disease
Huang, X., Sterling, N. W., Du, G., Sun, D., Stetter, C., Kong, L., Zhu, Y., Neighbors, J., Lewis, M., Chen, H., Hohl, R. & Mailman, R., Mar 1 2019, In : Movement Disorders. 34, 3, p. 386-395 10 p.
Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil
Sheehy, R. M., Kuder, C. H., Bachman, Z. & Hohl, R. J., Jan 1 2015, In : Cancer Biology and Therapy. 16, 8, p. 1259-1268 10 p.
Rhodamine 123
Change in erythropoietin pharmacokinetics following hematopoietic transplantation
Widness, J. A., Schmidt, R. L., Hohl, R. J., Goldman, F. D., Al-Huniti, N. H., Freise, K. J. & Veng-Pedersen, P., Jun 1 2007, In : Clinical pharmacology and therapeutics. 81, 6, p. 873-879 7 p.
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway
Chapel, S., Veng-Pedersen, P., Hohl, R., Schmidt, R. L., Mcguire, E. M. & Widness, J. A., Aug 2 2001, In : Journal of Pharmacology and Experimental Therapeutics. 298, 2, p. 820-824 5 p.
Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
Karp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., Ange, D., Buddharaju, L., Gojo, I., Edward Highsmith, W., Belly, R. T., Hohl, R. J., Rybak, M. E., Thibault, A. & Rosenblatt, J., Jun 1 2001, In : Blood. 97, 11, p. 3361-3369 9 p.
tipifarnib
Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB
Holstein, S. A., Wohlford-Lenane, C. L. & Hohl, R., Mar 22 2002, In : Journal of Biological Chemistry. 277, 12, p. 10678-10682 5 p.
Cyclodextrin complexation: Influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent
Kang, J., Kumar, V., Yang, D., Chowdhury, P. R. & Hohl, R., Feb 27 2002, In : European Journal of Pharmaceutical Sciences. 15, 2, p. 163-170 8 p.
Camptothecin
Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells
Henry, M. K., Nimbalkar, D., Hohl, R. & Quelle, F. W., Sep 10 2004, In : Experimental Cell Research. 299, 1, p. 257-266 10 p.
1-Phosphatidylinositol 4-Kinase
Defenses against oxidation in human erythrocytes: Role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs
Hohl, R. J., Kennedy, E. J. & Frischer, H., Apr 1991, In : The Journal of Laboratory and Clinical Medicine. 117, 4, p. 325-331 7 p.
Decarboxylation
Glutathione Disulfide
Glutathione Reductase
Contact Raymond Hohl, MD, PhD